Nikko Asset Management Americas’s Amneal Pharmaceuticals AMRX Stock Holding History

Nikko Asset Management Americas’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.7K	Buy	+3,339	New	+$45.8K	﹤0.01%	233

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Nikko Asset Management Americas's AMRX Position: Q2 2026 in Review

Nikko Asset Management Americas opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 3,339 shares worth $57.7K. The stake represents ﹤0.01% of the portfolio and ranks #233 among its holdings.

306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Nikko Asset Management Americas held 3,339 shares of Amneal Pharmaceuticals worth $57.7K as of Q2 2026.
Amneal Pharmaceuticals was a new Nikko Asset Management Americas position in Q2 2026.
Amneal Pharmaceuticals made up ﹤0.01% of Nikko Asset Management Americas's portfolio in Q2 2026, its #233 holding.
306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Nikko Asset Management Americas's 13F filing for Q2 2026, filed 13 Aug 2026.